Merck Research Laboratories Facilities Designated as “Milestones in Microbiology” Sites by the American Society for Micro...
18 October 2016 - 8:00AM
Business Wire
Merck (NYSE:MRK), known as MSD outside the United States and
Canada, announced today that Merck Research Laboratories (MRL)
facilities in Rahway, N.J., and West Point, Pa., have been
designated as “Milestones in Microbiology” sites by the American
Society for Microbiology (ASM) for their contributions to
anti-infectives and vaccines, respectively. This is the first time
a biopharmaceutical company has received this recognition. The ASM
Milestones in Microbiology program recognizes institutions and
scientists that have made significant contributions toward
advancing the science of microbiology.
“Merck is honored to be the first biopharmaceutical company to
receive this recognition from the American Society for Microbiology
as we celebrate our 125th anniversary,” said Dr. Roger M.
Perlmutter, president, Merck Research Laboratories. “We are proud
of our legacy of antimicrobial research and remain steadfast in our
commitment to treating and preventing infectious diseases.”
The MRL facilities were designated as ASM Milestones in
Microbiology sites in recognition of the company’s research and
development efforts including:
- Advancing a method of deep tank
fermentation, in collaboration with other pharmaceutical companies
and government agencies, which paved the way for the mass
production of penicillin.
- Working with Selman Waksman (Rutgers
University, N.J.) to secure one of the earliest formal
collaborations between private industry and academia. This
collaboration led to the demonstration that streptomycin was
effective for the treatment of tuberculosis.
- Establishing a natural product
screening program that enabled Merck researchers to develop several
new antibiotic medicines by culturing and screening organisms
sampled from sites all over the world.
- Developing a treatment for river
blindness (onchocerciasis) for which Merck scientist William
Campbell shared the 2015 Nobel Prize in Physiology or
Medicine.
- Developing a portfolio of vaccines for
the prevention of several viral and bacterial infections; research
led by the pioneering vaccinologist Dr. Maurice Hilleman.
“The Milestones in Microbiology
program includes prominent sites that fundamentally
impact the microbial sciences. From the perspective of the ASM,
Merck Research Laboratories has met and exceeded all the criteria
required for recognition as a Milestones site. We are especially
pleased to recognize it as the first industrial Milestones site,”
said Susan Sharp, president of the American Society for
Microbiology. For more information about ASM’s Milestones in
Microbiology program and a list of previously-designated sites,
visit www.asm.org/milestones-in-microbiology.
Merck’s Commitment to Infectious Diseases
For more than 80 years, Merck has contributed to the discovery
and development of novel medicines and vaccines to combat
infectious diseases. Merck currently has 10 candidates in Phase
2/Phase 3 clinical trials for the potential treatment or prevention
of infectious diseases.
About Merck
For 125 years, Merck has been a global health care leader
working to help the world be well. Merck is known as MSD outside
the United States and Canada. Through our prescription medicines,
vaccines, biologic therapies and animal health products, we work
with customers and operate in more than 140 countries to deliver
innovative health solutions. We also demonstrate our commitment to
increasing access to health care through far-reaching policies,
programs and partnerships. For more information, visit
www.merck.com and connect with us on Twitter, Facebook, YouTube and
LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, NJ, USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
There can be no guarantees with respect to pipeline products that
the products will receive the necessary regulatory approvals or
that they will prove to be commercially successful. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2015
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161017006081/en/
Media:Pam Eisele, 267-305-3558Ian McConnell,
908-740-1921Investor:Teri Loxam, 908-740-1986Amy Klug,
908-740-1898
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024